Impact of the Smoothened Inhibitor, IPI-926, on Smoothened Ciliary Localization and Hedgehog Pathway Activity

• Marisa O. Peluso,

  Affiliation Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America

  ⨯
• Veronica T. Campbell,

  Affiliation Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America

  ⨯
• Joseph A. Harari,

  Affiliation Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America

  ⨯
• Thomas T. Tibbitts,

  Affiliation Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America

  ⨯
• Jennifer L. Proctor,

  Affiliation Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America

  ⨯
• Nigel Whitebread,

  Affiliation Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America

  ⨯
• James M. Conley,

  Affiliation Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America

  ⨯
• Kerry F. White,

  Affiliation Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America

  ⨯
• Jeffery L. Kutok,

  Affiliation Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America

  ⨯
• Margaret A. Read,

  Affiliation Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America

  ⨯
• Karen McGovern,

  Affiliation Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America

  ⨯
• Kerrie L. Faia

  * E-mail: Kerrie.Faia@infi.com

  Affiliation Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts, United States of America

  ⨯